Arcturus to present Phase 2 ARCT-810 clinical data in OTC deficiency on Sept. 23
Bitget2026/09/18 13:01- Arcturus scheduled a virtual event for Sept. 23, 2026 to present Phase 2 data for ARCT-810 in OTC deficiency.
- Results have not been presented yet; a summary is slated for release ahead of the presentation.
- Update will also cover the company’s mRNA liver therapeutics platform, signaling continued investment in rare-disease liver programs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.


Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000
